Antiretrovial Drug Treatment

Browse more sub-categories

Active Resources: 31

Image Library

Patient Information

Articles: 9

  • CROI 2017: Doravirine Noninferior to Darunavir + Ritonavir in Initial Treatment

    Doravirine is an investigational NNRTI that is active in vitro against many common NNRTI resistance mutations (including K103N, Y181C, and E138K). It is given once daily, has no food restrictions, and can be given with acid-blocking medications. In a Phase 2 study of treatment-...

  • CROI 2017: Bictegravir and Dolutegravir, Head-to-Head Comparison

     

    Bictegravir is an investigational integrase inhibitor that is dosed once daily, unboosted. It is active in vitro against many viruses with integrase resistance mutations. A Phase 2 double-blind placebo-controlled study randomized treatment-naive patients (n...

  • CROI 2017: Dolutegravir in 2-Drug Simplification Studies

    In recent years, a number of studies have evaluated 2-drug or even 1-drug ARV regimens, either in initial therapy or in switch regimens for patients with virologic suppression on 3-drug therapy. In general, these have not been as successful in achieving or maintaining virologic suppression as...

  • START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV

    The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and...

  • TAF: New Data on Tenofovir Alafenamide Fumarate


    Tenofovir alafenamide fumarate (TAF) is an investigational prodrug of tenofovir that in studies to date appears to have less renal and bone toxicity than the current tenofovir product, tenofovir disoproxil fumarate (TDF). This is because TAF is metabolized to tenofovir in lymphocytes and...

  • Rilpivirine Updates: Approved for Adolescents; Possible Risk of Depression

    The U.S. Food and Drug Administration has approved rilpivirine for use in adolescents 12 to 18 years of age; it is not recommended for younger children. As in adults, it is suggested for use in ARV-naive individuals with HIV RNA levels of ≤100,000 copies/mL. The dosage is 25 mg...

  • Pyrimethamine Availability

    Pyrimethamine is no longer available in retail pharmacies in the United States, though it is available through a commercial specialty pharmacy program (the application process, approval, and delivery of the medication will take at least 2 days; for information on ordering, click...

  • Adult and Adolescent Guidelines: Major Changes

    The U.S. Department of Health and Human Services has released new treatment guidelines for adults and adolescents, and these contain some important changes. Key among these is a major shakeup in the "Recommended Regimen Options" for initial therapy. 

    Efavirenz/TDF/FTC (Atripla) has...
  • Two New Boosted-PI Coformulations

    Two boosted protease inhibitor (PI) coformulations have just been approved by the FDA. These are:

    Darunavir 800 mg + cobicistat 150 mg (Prezcobix), andAtazanavir 300 mg + cobicistat 150 mg (Evotaz)

    In these fixed-dose combinations, cobicistat is used as the pharmacokinetic booster of the PI...

Day Title
6/28
ART Resistance for Beginners
Event type: Webinars
7/13
Locking Down HIV & HCV: Treating Infectious Diseases in Correctional Settings
Day Title
3/24
American Pharmacists Association Annual Meeting and Exposition 2017